Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.

Calarge CA, Miller del D.

J Child Adolesc Psychopharmacol. 2011 Apr;21(2):163-9. doi: 10.1089/cap.2010.0038. Epub 2011 Apr 12.

2.

National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007.

Comer JS, Olfson M, Mojtabai R.

J Am Acad Child Adolesc Psychiatry. 2010 Oct;49(10):1001-10. doi: 10.1016/j.jaac.2010.07.007. Epub 2010 Sep 1.

3.

Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study.

Gebhardt S, Theisen FM, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg JC, K├╝hnau W, Schmidtke J, Remschmidt H, Hebebrand J.

J Clin Pharm Ther. 2010 Apr;35(2):207-11. doi: 10.1111/j.1365-2710.2009.01084.x.

PMID:
20456740
4.

A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.

Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA.

J Clin Psychiatry. 2010 Mar;71(3):338-47. doi: 10.4088/JCP.08m04595gre.

5.

Trends in antipsychotic drug use by very young, privately insured children.

Olfson M, Crystal S, Huang C, Gerhard T.

J Am Acad Child Adolesc Psychiatry. 2010 Jan;49(1):13-23.

PMID:
20215922
6.

Increased food intake and energy expenditure following administration of olanzapine to healthy men.

Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, Most MM, Fryburg DA.

Obesity (Silver Spring). 2010 Aug;18(8):1646-51. doi: 10.1038/oby.2010.6. Epub 2010 Feb 4.

7.

Validity of Clinical Body Weight Measures as Substitutes for Missing Data in a Randomized Trial.

Arterburn D, Ichikawa L, Ludman EJ, Operskalski B, Linde JA, Anderson E, Rohde P, Jeffery RW, Simon GE.

Obes Res Clin Pract. 2008 Dec;2(4):277-281.

8.

Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study.

Findling RL, Nyilas M, Forbes RA, McQuade RD, Jin N, Iwamoto T, Ivanova S, Carson WH, Chang K.

J Clin Psychiatry. 2009 Oct;70(10):1441-51. doi: 10.4088/JCP.09m05164yel.

PMID:
19906348
9.

Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality.

Penzner JB, Dudas M, Saito E, Olshanskiy V, Parikh UH, Kapoor S, Chekuri R, Gadaleta D, Avedon J, Sheridan EM, Randell J, Malhotra AK, Kane JM, Correll CU.

J Child Adolesc Psychopharmacol. 2009 Oct;19(5):563-73. doi: 10.1089/cap.2009.0051.

10.

Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents.

Calarge CA, Ellingrod VL, Zimmerman B, Acion L, Sivitz WI, Schlechte JA.

Psychiatr Genet. 2009 Dec;19(6):320-7.

11.

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.

Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK.

JAMA. 2009 Oct 28;302(16):1765-73. doi: 10.1001/jama.2009.1549. Erratum in: JAMA. 2009 Dec 2;302(21):2322.

12.

Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study.

Haas M, Delbello MP, Pandina G, Kushner S, Van Hove I, Augustyns I, Quiroz J, Kusumakar V.

Bipolar Disord. 2009 Nov;11(7):687-700. doi: 10.1111/j.1399-5618.2009.00750.x.

PMID:
19839994
13.

Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.

Simon V, van Winkel R, De Hert M.

J Clin Psychiatry. 2009 Jul;70(7):1041-50. Review.

PMID:
19653979
14.

Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents.

Calarge CA, Acion L, Kuperman S, Tansey M, Schlechte JA.

J Child Adolesc Psychopharmacol. 2009 Apr;19(2):101-9. doi: 10.1089/cap.2008.007.

15.

Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.

Calarge CA, Ellingrod VL, Acion L, Miller DD, Moline J, Tansey MJ, Schlechte JA.

Pharmacogenet Genomics. 2009 May;19(5):373-82. doi: 10.1097/FPC.0b013e328329a60f.

16.

Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism.

Steinberger J, Daniels SR, Eckel RH, Hayman L, Lustig RH, McCrindle B, Mietus-Snyder ML; American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism.

Circulation. 2009 Feb 3;119(4):628-47. doi: 10.1161/CIRCULATIONAHA.108.191394. Epub 2009 Jan 12. No abstract available.

17.

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.

Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA.

Am J Psychiatry. 2008 Nov;165(11):1420-31. doi: 10.1176/appi.ajp.2008.08050756. Epub 2008 Sep 15. Erratum in: Am J Psychiatry. 2008 Nov;165(11):1495.

PMID:
18794207
18.

Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder.

Lipkovich I, Jacobson JG, Hardy TA, Hoffmann VP.

BMC Psychiatry. 2008 Sep 15;8:78. doi: 10.1186/1471-244X-8-78.

19.

Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone.

Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, Rauh R, Remschmidt H, Schulz E, Warnke A.

J Neural Transm (Vienna). 2008 Nov;115(11):1599-608. doi: 10.1007/s00702-008-0105-9. Epub 2008 Sep 9.

PMID:
18779922
20.

Insulin resistance: the link between obesity and cardiovascular disease.

Reaven GM.

Endocrinol Metab Clin North Am. 2008 Sep;37(3):581-601, vii-viii. doi: 10.1016/j.ecl.2008.06.005. Review.

PMID:
18775353
Items per page

Supplemental Content

Write to the Help Desk